sdr42e1 Antibody

What is SDR42E1 and what cellular functions does it perform?

SDR42E1 (Short Chain Dehydrogenase/Reductase Family 42E, Member 1) belongs to the large family of short-chain dehydrogenases/reductases (SDR) involved in steroid biosynthesis. It demonstrates oxidoreductase activity, acting on the CH-OH group of donors, with NAD or NADP as acceptor. Recent research has revealed its critical role in cholesterol metabolism and the maintenance of connective tissue integrity . The protein is predicted to be an integral component of the membrane, functioning as a multi-pass membrane protein .

Gene ontology annotations indicate that SDR42E1 has 3-beta-hydroxy-delta5-steroid dehydrogenase activity, suggesting a direct role in steroid hormone pathway regulation . Mutations in this gene have been associated with a syndrome affecting both ocular and cutaneous tissues, as well as genital development, highlighting its multifaceted physiological importance .

What applications are SDR42E1 antibodies commonly used for in laboratory research?

SDR42E1 antibodies serve multiple critical research applications:

These antibodies are instrumental in elucidating SDR42E1's subcellular localization, expression patterns across tissues, interactions with other proteins, and functional changes resulting from mutations. Current commercially available antibodies show reactivity to human and mouse SDR42E1, with some predicted cross-reactivity to rat .

What are the optimal storage and handling conditions for SDR42E1 antibodies?

Proper storage and handling are essential for maintaining antibody integrity and experimental reproducibility:

Most SDR42E1 antibodies should be stored at -20°C for long-term preservation. Commercial preparations are typically provided either in lyophilized form or in solution with stabilizers . For reconstitution of lyophilized antibodies, manufacturers recommend using 100 μl of sterile distilled H₂O with 50% glycerol .

Buffer compositions generally include PBS with either 40-50% glycerol, 0.5-1% BSA, and 0.02% sodium azide at pH 7.2 to maintain stability . Repeated freeze-thaw cycles significantly degrade antibody quality and should be strictly avoided; aliquoting upon first thaw is recommended for antibodies requiring multiple uses .

What methodological considerations are important when using SDR42E1 antibodies in Western blot experiments?

Successful Western blot experiments with SDR42E1 antibodies require attention to several key parameters:

• Sample preparation: Complete lysis buffers containing protease inhibitors are essential as SDR42E1 is a membrane protein requiring effective extraction.

• Dilution optimization: While manufacturers recommend dilutions of 1:500-1:2000, researchers should conduct preliminary experiments to determine optimal concentration for their specific sample type .

• Detection system: Secondary antibody selection should match the host species (typically rabbit for available polyclonal antibodies) .

• Molecular weight verification: The observed molecular weight for SDR42E1 is approximately 44 kDa; significant deviations may indicate post-translational modifications or isoforms .

• Positive controls: Including samples from tissues known to express SDR42E1 (based on tissue expression databases) provides essential experimental validation.

• Blocking optimization: Due to the hydrophobic nature of this multi-pass membrane protein, blocking conditions may require optimization beyond standard protocols to reduce non-specific binding.

How can researchers validate the specificity of SDR42E1 antibodies?

Antibody validation is critical for ensuring experimental reliability:

• Genetic controls: Testing in CRISPR/Cas9 knockout or knockdown models provides the gold standard for specificity validation. BioGRID ORCS database catalogues SDR42E1 CRISPR screens that could serve as reference or experimental controls .

• Multiple antibody comparison: Using different antibodies targeting distinct epitopes of SDR42E1 can confirm signal specificity.

• Peptide competition assays: Pre-incubating the antibody with excess immunizing peptide should abolish specific signals if the antibody is truly specific.

• Cross-species reactivity assessment: Comparing detection patterns across species with known sequence homology (human SDR42E1 shares 83% sequence identity with mouse and 78% with rat orthologs) can provide additional confidence in specificity .

• Mass spectrometry verification: For immunoprecipitation applications, mass spectrometry analysis of pulled-down proteins provides definitive validation of antibody specificity.

How can SDR42E1 antibodies be used to investigate its role in steroid biosynthesis?

Investigating SDR42E1's function in steroid biosynthesis requires sophisticated experimental approaches:

• Co-localization studies: Combine SDR42E1 antibodies with markers of steroidogenic organelles (mitochondria, smooth endoplasmic reticulum) to determine subcellular compartmentalization of steroid synthesis functions.

• Enzyme activity assays: Use SDR42E1 antibodies to immunoprecipitate the protein from cellular lysates, followed by in vitro enzymatic activity measurements with steroid substrates to assess its oxidoreductase functions.

• Steroid pathway component interactions: Apply co-immunoprecipitation with SDR42E1 antibodies to identify protein interactions with known steroidogenic enzymes or regulatory proteins.

• Tissue-specific expression correlation: Compare SDR42E1 expression patterns (using immunohistochemistry) with steroidogenic tissues to establish physiological relevance of its functional role.

• Mutation impact studies: Utilize SDR42E1 antibodies to analyze expression and localization changes in cells expressing variants such as the p.Arg154Gln mutation associated with steroid synthesis defects and connective tissue abnormalities .

How might the homozygous missense mutation c.461G > A (p.Arg154Gln) in SDR42E1 affect antibody recognition?

The p.Arg154Gln mutation in SDR42E1 creates specific challenges and considerations for antibody-based studies:

This mutation results in a destabilizing effect on the protein with a ΔΔG value of -1.039 kcal/mol, potentially altering protein conformation . Researchers should consider whether their antibody's epitope includes or is conformationally affected by the arginine at position 154. Epitope mapping is recommended when studying this mutation.

For antibodies targeting regions containing the mutation site, binding affinity might be substantially reduced in mutant samples. Researchers investigating this mutation should perform parallel experiments with antibodies targeting different epitopes to ensure comprehensive protein detection. Additionally, when studying patient samples with this mutation, altered protein expression levels may reflect either genuine biological changes or reduced antibody affinity to the mutant protein – careful controls are essential to distinguish these possibilities.

What are the emerging applications of SDR42E1 antibodies in studying oculocutaneous genital syndrome?

The novel association between SDR42E1 mutations and oculocutaneous genital syndrome opens several research avenues:

• Diagnostic immunohistochemistry: SDR42E1 antibodies can be used to examine protein expression patterns in patient tissue samples, potentially revealing localization abnormalities in affected tissues.

• Developmental expression studies: Immunohistochemical analysis of SDR42E1 during embryonic development could elucidate its temporal role in connective tissue formation and genital development.

• Pathway interaction analysis: Co-immunoprecipitation studies with SDR42E1 antibodies can identify interacting proteins in normal versus disease states, revealing disrupted molecular pathways.

• Cholesterol metabolism investigations: Since affected patients demonstrate low cholesterol levels, SDR42E1 antibodies can help track protein localization relative to cholesterol transport machinery .

• Therapeutic target validation: As understanding of this syndrome develops, SDR42E1 antibodies will be valuable for validating potential therapeutic approaches targeting the protein or its regulatory pathways.

What are common technical challenges when working with SDR42E1 antibodies?

Researchers should anticipate several technical challenges:

• Membrane protein extraction efficiency: As a multi-pass membrane protein, SDR42E1 may require optimized lysis conditions to achieve complete extraction and prevent aggregation during sample preparation.

• Cross-reactivity with paralogs: SDR42E1 has important paralogs, including SDR42E2 . Researchers should verify that their antibody doesn't cross-react with these related proteins, particularly in tissues where both are expressed.

• Post-translational modifications: Potential modifications may alter antibody recognition or cause unexpected mobility shifts in gel electrophoresis.

• Background in immunohistochemistry: Optimization of antigen retrieval methods is often necessary for membrane proteins like SDR42E1 to achieve specific staining while minimizing background.

• Species-specific considerations: While current antibodies show reactivity to human and mouse SDR42E1, with some predicted cross-reactivity to rat, sequence divergence may affect epitope recognition in less common research models .

What methodological approaches are recommended for studying SDR42E1 interactions with cholesterol metabolism pathways?

Investigating SDR42E1's role in cholesterol metabolism requires specialized approaches:

• Cholesterol depletion studies: Compare SDR42E1 localization and expression before and after cellular cholesterol depletion using SDR42E1 antibodies.

• Co-immunoprecipitation with cholesterol regulatory proteins: Use SDR42E1 antibodies to pull down protein complexes and identify interactions with cholesterol synthesis enzymes or transporters.

• Lipid raft association analysis: Employ detergent-resistant membrane fractionation followed by Western blotting with SDR42E1 antibodies to determine its association with cholesterol-rich membrane domains.

• Cholesterol measurement in cellular models: Correlate SDR42E1 protein levels (quantified using antibodies) with cellular cholesterol content in various experimental conditions.

• Tissue correlation studies: Apply immunohistochemistry with SDR42E1 antibodies across tissues with varying cholesterol synthetic requirements to establish physiological patterns.